ULBI Ultralife Corporation

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 26, 2023

Date of Report (Date of Earliest Event Reported)

ULTRALIFE CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

000-20852

16-1387013

(State of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

2000 Technology Parkway, Newark, New York 14513

(Address of principal executive offices) (Zip Code)

(315) 332-7100

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Common Stock, $0.10 par value per share

ULBI

NASDAQ

(Title of each class)

(Trading Symbol)

(Name of each exchange on which registered)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Exhibit Number		Exhibit Description
99.1		Press Release of Ultralife Corporation dated October 26, 2023
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Date: October 26, 2023		ULTRALIFE CORPORATION
	By:	/s/ Philip A. Fain
		Philip A. Fain
		Chief Financial Officer and Treasurer

 

Exhibit 99.1

 

 

Ultralife Corporation Reports Third Quarter Results

 

 

NEWARK, N.Y. – October 26, 2023 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the third quarter ended September 30, 2023 with the following highlights:

 

●

Sales of $39.5 million representing an 18.8% year-over-year increase

●

Operating income of $2.1 million versus a loss of $0.6 million for the 2022 third quarter

●

Adjusted EPS of $0.10 compared to a loss of $0.03 for the 2022 third quarter

●

Adjusted EBITDA of $3.5 million representing a 177.3% year-over-year increase

●

Backlog of $101.1 million exiting the 2023 third quarter

 

“Driven by continuing strong demand from our government/defense and medical customers, sales grew 19% for both the 2023 third quarter and the first nine months to $39.5 million and $114.1 million, respectively, over the prior year periods. We continue to focus on recapturing gross margin through price realization, lean manufacturing initiatives and level-loaded production, which resulted in a year-over-year improvement in gross margin of 460 basis points to 24.8% for the third quarter. On the strength of higher sales, gross margin improvement and disciplined spending, operating profit of $2.1 million far exceeded the operating loss of $0.6 million from the year-earlier quarter. Finally, our efforts to strengthen our relationships with key customers using our global new product development resources are bearing fruit as we continue to sustain our backlog in excess of $100 million,” said Mike Manna, President and Chief Executive Officer. “As we close out 2023 with a strong backlog, we are well positioned to continue our profitable growth and to generate incremental cashflow to reduce our acquisition debt and further invest in our businesses, including new product development, strategic capital expenditures and accretive acquisitions.”

 

Third Quarter 2023 Financial Results

 

Revenue was $39.5 million, an increase of $6.3 million, or 18.8%, as compared to revenue of $33.2 million for the third quarter of 2022. Overall, government/defense sales increased 48.1% and commercial sales increased 5.6% over the 2022 period. Battery & Energy Products sales increased 11.7% to $31.9 million compared to $28.6 million last year, reflecting increases of 36.2% in government/defense sales and 37.9% in medical battery sales, partially offset by decreases of 1.8% in oil & gas market sales and 14.9% in other commercial sales. Communications Systems sales increased by 62.7% to $7.6 million compared to $4.7 million for the same period last year, primarily attributable to shipments of vehicle-amplifier adaptors to a global defense contractor for the U.S. Army and of integrated systems of amplifiers and radio vehicle mounts to a major international defense contractor under an ongoing allied country government/defense modernization program. Our total backlog exiting the 2023 third quarter was $101.1 million with over $35 million of the total backlog due to ship over the remaining three months of 2023.

 

Gross profit was $9.8 million, or 24.8% of revenue, compared to $6.7 million, or 20.2% of revenue, for the same quarter a year ago. Battery & Energy Products gross margin was 24.2%, compared to 18.7% last year, primarily due to more efficiencies and higher cost absorption resulting from a concerted effort to level-load production more evenly across the 2023 quarter, as well as improved price realization. Communications Systems gross margin was 27.0% compared to 29.5% last year, primarily due to inefficiencies caused by component delays from suppliers, partially offset by higher factory volume.

 

Operating expenses were $7.6 million, compared to $7.3 million for the 2022 third quarter. Operating expenses were 19.3% of revenue compared to 22.0% of revenue for the year-earlier period.

 

The combination of higher gross profit and leveraging of operating expenses resulted in a $2.7 million increase in operating income to $2.1 million from an operating loss of $0.6 million last year.

 

Net income was $1.3 million or $0.08 per diluted share on a GAAP basis, compared to a net loss of $0.2 million or $0.01 per diluted share for the third quarter of 2022. Adjusted EPS was $0.10 on a diluted basis for the third quarter of 2023, compared to a loss of $0.03 for the 2022 period. Adjusted EPS excludes the provision for deferred taxes of $0.4 million which primarily represents non-cash charges for U.S. taxes which we expect will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future.

 

Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense, was $3.5 million for the third quarter of 2023, or 8.8% of sales, compared to $1.3 million, or 3.8% of sales, for the year-earlier period.

 

See the “Non-GAAP Financial Measures” section of this release for a reconciliation of adjusted EPS to EPS and adjusted EBITDA to net income attributable to Ultralife Corporation.

 

 

About Ultralife Corporation

 

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government/defense and commercial customers across the globe.

 

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.

 

 

Conference Call Information

 

Ultralife will hold its third quarter earnings conference call today at 8:30 AM ET.

 

To ensure a fast and reliable connection to our investor conference call, we now require participants dialing in by phone to register using the following link prior to the call: https://register.vevent.com/register/BI7f14d2264d2242c1adb217d21d75ab21. This will eliminate the need to speak with an operator. Once registered, dial-in information will be provided along with a personal identification number. Should you register early and misplace your details, you can simply click back on this same link at any time to register and view this information again. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

 

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include the impact of COVID-19 and related supply chain disruptions, potential reductions in revenues from key customers, acceptance of our new products on a global basis and uncertain global economic conditions. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS (Dollars in Thousands)

(Unaudited)

ASSETS

 

		September 30, 2023				December 31, 2022
Current Assets:
Cash		$	9,301			$	5,713
Trade Accounts Receivable, Net			27,189				27,779
Inventories, Net			46,634				41,192
Prepaid Expenses and Other Current Assets			6,429				4,304
Total Current Assets			89,553				78,988
Property, Plant and Equipment, Net			21,166				21,716
Goodwill			37,357				37,428
Other Intangible Assets, Net			15,270				15,921
Deferred Income Taxes, Net			10,728				12,069
Other Non-Current Assets			2,035				2,308
Total Assets		$	176,109			$	168,430
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Accounts Payable		$	13,470			$	16,074
Current Portion of Long-Term Debt			2,000				2,000
Accrued Compensation and Related Benefits			2,467				2,890
Accrued Expenses and Other Current Liabilities			8,449				7,949
Total Current Liabilities			26,386				28,913
Long-Term Debt, Net			24,108				19,310
Deferred Income Taxes			1,825				1,917
Other Non-Current Liabilities			2,032				1,887
Total Liabilities			54,351				52,027
Shareholders' Equity:
Common Stock			2,075				2,057
Capital in Excess of Par Value			188,852				187,405
Accumulated Deficit			(43,627	)			(47,951	)
Accumulated Other Comprehensive Loss			(4,176	)			(3,750	)
Treasury Stock			(21,484	)			(21,484	)
Total Ultralife Equity			121,640				116,277
Non-Controlling Interest			118				126
Total Shareholders’ Equity			121,758				116,403
Total Liabilities and Shareholders' Equity		$	176,109			$	168,430

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(In Thousands Except Per Share Amounts)

(Unaudited)

 

 

		Three-Month Period Ended								Nine-Month Period Ended
		September 30,				September 30,				September 30,				September 30,
		2023				2022				2023				2022
Revenues:
Battery & Energy Products		$	31,919			$	28,583			$	94,250			$	87,873
Communications Systems			7,569				4,651				19,846				7,860
Total Revenues			39,488				33,234				114,096				95,733
Cost of Products Sold:
Battery & Energy Products			24,191				23,238				72,467				68,656
Communications Systems			5,523				3,281				13,831				5,758
Total Cost of Products Sold			29,714				26,519				86,298				74,414
Gross Profit			9,774				6,715				27,798				21,319
Operating Expenses:
Research and Development			1,869				1,896				5,679				5,425
Selling, General and Administrative			5,770				5,405				16,293				15,982
Total Operating Expenses			7,639				7,301				21,972				21,407
Operating Income (Loss)			2,135				(586	)			5,826				(88	)
Other Income (Expense)			(386	)			254				178				22
Income (Loss) Before Income Taxes			1,749				(332	)			6,004				(66	)
Income Tax Provision (Benefit)			446				(90	)			1,688				(171	)
Net Income (Loss)			1,303				(242	)			4,316				105
Net (Loss) Income Attributable to Non-Controlling Interest			(27	)			(3	)			(8	)			-
Net Income (Loss) Attributable to Ultralife Corporation		$	1,330			$	(239	)		$	4,324			$	105
Net Income (Loss) Per Share Attributable to Ultralife Common Shareholders – Basic		$	.08			$	(.01	)		$	.27			$	.01
Net Income (Loss) Per Share Attributable to Ultralife Common Shareholders – Diluted		$	.08			$	(.01	)		$	.27			$	.01
Weighted Average Shares Outstanding – Basic			16,238				16,133				16,172				16,122
Weighted Average Shares Outstanding – Diluted			16,303				16,133				16,174				16,144

 

 

Non-GAAP Financial Measures

 

 

Adjusted EBITDA

 

In evaluating our business, we consider and use adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance in addition to U.S. Generally Accepted Accounting Principles (“GAAP”) financial measures. We define adjusted EBITDA as net income attributable to Ultralife Corporation before net interest expense, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We reconcile adjusted EBITDA to net income attributable to Ultralife Corporation, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CALCULATION OF ADJUSTED EBITDA

(Dollars in Thousands)

(Unaudited)

 

 

		Three-Month Period Ended								Nine-Month Period Ended
		September 30, 2023				September 30, 2022				September 30, 2023				September 30, 2022
Net Income (Loss) Attributable to Ultralife Corporation		$	1,330			$	(239	)		$	4,324			$	105
Adjustments:
Interest Expense, Net			586				272				1,450				583
Income Tax Provision (Benefit)			446				(90	)			1,688				(171	)
Depreciation Expense			760				815				2,282				2,450
Amortization Expense			227				318				663				969
Stock-Based Compensation Expense			131				179				424				552
Cyber-Insurance Policy Deductible			-				-				100				-
Non-Cash Purchase Accounting Adjustment			-				-				-				55
Adjusted EBITDA		$	3,480			$	1,255			$	10,931			$	4,543

 

 

Adjusted Earnings Per Share

 

In evaluating our business, we consider and use adjusted EPS, a non-GAAP financial measure, as a supplemental measure of our business performance. We define adjusted EPS as net income attributable to Ultralife Corporation excluding the provision (benefit) for deferred income taxes divided by our weighted average shares outstanding on both a basic and diluted basis. We believe that this information is useful in providing period-to-period comparisons of our results by reflecting the portion of our tax provision that we expect will be predominantly offset by our U.S. net operating loss carryforwards and other tax credits for the foreseeable future. We reconcile adjusted EPS to EPS, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EPS as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EPS to EPS and net income attributable to Ultralife Corporation.

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CALCULATION OF ADJUSTED EPS

(In Thousands Except Per Share Amounts)

(Unaudited)

 

 

 

		Three-Month Period Ended
		September 30, 2023												September 30, 2022
		Amount				Per Basic Share				Per Diluted Share				Amount				Per Basic Share				Per Diluted Share
Net Income (Loss) Attributable to Ultralife Corporation		$	1,330			$	.08			$	.08			$	(239	)		$	(.01	)		$	(.01	)
Deferred Tax Provision (Benefit)			357				.02				.02				(308	)			(.02	)			(.02	)
Adjusted Net Income (Loss)		$	1,687			$	.10			$	.10			$	(547	)		$	(.03	)		$	(.03	)
Weighted Average Shares Outstanding							16,238				16,303								16,133				16,133

 

 

		Nine-Month Period Ended
		September 30, 2023												September 30, 2022
		Amount				Per Basic Share				Per Diluted Share				Amount				Per Basic Share				Per Diluted Share
Net Income Attributable to Ultralife Corporation		$	4,324			$	.27			$	.27			$	105			$	.01			$	.01
Deferred Tax Provision (Benefit)			1,245				.07				.07				(683	)			(.05	)			(.05	)
Adjusted Net Income (Loss)		$	5,569			$	.34			$	.34			$	(578	)		$	(.04	)		$	(.04	)
Weighted Average Shares Outstanding							16,172				16,174								16,122				16,144

 

 

Company Contact:

Ultralife Corporation

Philip A. Fain

(315) 210-6110

pfain@ulbi.com

Investor Relations Contact:

LHA

Jody Burfening

(212) 838-3777

jburfening@lhai.com

 

v3.23.3

Document And Entity Information	Oct. 26, 2023
Document Information [Line Items]
Entity, Registrant Name	ULTRALIFE CORPORATION
Document, Type	8-K
Document, Period End Date	Oct. 26, 2023
Entity, Incorporation, State or Country Code	DE
Entity, File Number	000-20852
Entity, Tax Identification Number	16-1387013
Entity, Address, Address Line One	2000 Technology Parkway
Entity, Address, City or Town	Newark
Entity, Address, State or Province	NY
Entity, Address, Postal Zip Code	14513
City Area Code	315
Local Phone Number	332-7100
Title of 12(b) Security	Common Stock
Trading Symbol	ULBI
Security Exchange Name	NASDAQ
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity, Emerging Growth Company	false
Amendment Flag	false
Entity, Central Index Key	0000875657

---